Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ABBVIE LIMITED,Fixed duration venetoclax with obinutuzumab,"Chronic lymphocytic leukaemia (CLL),  previously untreated",Fixed duration venetoclax with obinutuzumab,Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
